Centers for Disease Control and Prevention
Return to CDC Influenza | CDC Home
INFLUENZA SUMMARY UPDATE
(Week ending March 17, 2001-Week 11)
The following information may be quoted:
Synopsis: During week 11 (March 11-17, 2001)*, 5 % of the specimens tested by WHO and NREVSS laboratories were positive for influenza. The proportion of patient visits to sentinel physicians for influenza-like illness was within baseline levels of 0 % to 3 % in the United States overall and in 8 of 9 surveillance regions. The proportion of deaths attributed to pneumonia and influenza was 7,6 %. This percentage is below the epidemic threshold for this time of year. Six state and territorial health departments reported regional influenza activity**, 37 reported sporadic influenza activity, and 7 reported no influenza activity.
For the current season, the overall national percentage of respiratory specimens positive for influenza appears to have peaked at 24 % at the end of January (week 4). During the past 3 seasons, the peak percentages of respiratory specimens positive for influenza viruses have ranged from 28 % to 33 %. For this season, the percentage of patient visits to sentinel physicians for influenza-like illness appears to have peaked at 4 % in mid to late January. During the past 3 seasons, the peak percentages for such visits ranged between 5 % and 6 %.
U.S. World Health Organization (WHO) and National Respiratory And Enteric Virus Surveillance System(NREVSS) Collaborating Laboratory Reports *: During week 11, WHO and NREVSS laboratories reported 1 155 specimens tested for influenza viruses, of which 52 (5 %) were positive. One (2 %) was an influenza A (H3N2) virus, 9 (17 %) were unsubtyped influenza A viruses, and 42 (81 %) were influenza B viruses. During the past 3 weeks (weeks 9-11), the percentage of isolates nationwide that were influenza B was 73 % and during those weeks influenza B viruses have predominated (range 53 % to 95 %) in all 9 surveillance regions.*** In the New England, South Atlantic, and East North Central regions, the percentage of specimens testing positive for influenza in the past 3 weeks ranged from 10 % to 13 %. Between 5 % and 9 % of specimens tested for influenza over the past 3 weeks in the East South Central, West South Central, Mountain, Mid-Atlantic, and West North Central regions were positive. Two percent of specimens tested for influenza over the past 3 weeks in the Pacific region were positive.
Since October 1, WHO and NREVSS laboratories have tested a total of 67 198 specimens for influenza viruses, and 8 610 (13 %) were positive. Of the 8 610 isolates identified, 4 966 (58 %) were influenza type A and 3 644 (42 %) were influenza type B. One thousand eight hundred and fifty-two (37 %) of the 4 966 influenza A viruses identified have been subtyped; 1 772 (96 %) were A (H1N1) and 80 (4 %) were A (H3N2). Influenza A viruses have predominated (range 55 % to 68 %) in the East South Central, West South Central, West North Central, South Atlantic, and East North Central regions, and influenza B viruses have predominated (range 55 % to 59 %) in the Pacific and Mid-Atlantic regions. The New England and Mountain regions have reported approximately equal numbers of influenza A and influenza B isolates this season.
View Chart Data
Antigenic Characterization of Viral Isolates: CDC has antigenically characterized 468 influenza viruses received from U.S. laboratories since October 1. Of the 275 influenza A (H1N1) isolates that have been characterized, 262 (95 %) were similar to A/New Caledonia/20/99, the H1N1 component of the 2000-01 influenza vaccine, and 13 (5 %) were similar to A/Bayern/07/95. Although A/Bayern-like viruses are antigenically distinct from the A/New Caledonia-like viruses, the A/New Caledonia/20/99 vaccine strain produces high titers of antibody that cross-react with A/Bayern/07/95-like viruses. Of the 16 influenza A (H3N2) viruses that have been characterized, all were antigenically similar to the vaccine strain A/Panama/2007/99. Of the 177 influenza B viruses characterized, 29 (16 %) were similar to the vaccine strain, B/Beijing/184/93, and 148 (84 %) were more closely related antigenically to the B/Sichuan/379/99 reference strain. It should be noted that the B/Sichuan virus exhibits cross-reactivity with the vaccine strain.
Pneumonia and Influenza (P&I) Mortality: During week 11, the percentage of all deaths due to P&I as reported by the vital statistics offices of 122 U.S. cities was 7,6 %. This percentage is below the epidemic threshold of 8,7 % for week 11.
Influenza Morbidity Reports from U.S. Sentinel Physicians*: During week 11, 1 % of patient visits to U.S. sentinel physicians were due to influenza-like illness (ILI). The percentage of patient visits for ILI was above baseline levels of 0 % to 3 % only in the Pacific region (4 %).
View Chart Data
Influenza Activity as Assessed by State and Territorial Epidemiologists**: Influenza activity was reported as regional in 6 states (Arizona, Colorado, Kentucky, Maryland, Ohio, and Tennessee) and sporadic in 37 states. Seven states reported no influenza activity.
* Reporting is incomplete for this week. Numbers may change as more reports are received.
** Influenza activity is defined as influenza-like illness and/or culture-confirmed influenza.
*** Surveillance Regions: New England (Connecticut, Maine, Massachusetts, New Hampshire, Vermont, Rhode Island); Mid-Atlantic (New Jersey, New York City, Pennsylvania, Upstate New York); East North Central (Illinois, Indiana, Michigan, Ohio, Wisconsin); West North Central (Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota); South Atlantic (Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, Washington, D.C., West Virginia); East South Central (Alabama, Kentucky, Mississippi, Tennessee); West South Central (Arkansas, Louisiana, Oklahoma, Texas); Mountain (Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming); Pacific (Alaska, California, Hawaii, Oregon, Washington)
Report prepared: March 22, 2001
Top | CDC Influenza | CDC Home
National Center for Infectious Diseases
Centers for Disease Control and Prevention